A phase I study of high-dose, intermittent sunitinib in patients with solid tumors.
Phase of Trial: Phase I/II
Latest Information Update: 18 Jul 2019
Price : $35 *
At a glance
- Drugs Sunitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms SUNRISE
- 26 Dec 2018 Status changed from recruiting to completed, as reported in an article published in the Journal of Clinical Oncology.
- 26 Dec 2018 Results published in the Journal of Clinical Oncology
- 06 Jun 2017 Results assessing the feasibility and tolerability of high dose, once weekly (1w) or once every two weeks (2w) sunitinib in patients with advanced solid tumors, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.